141 related articles for article (PubMed ID: 32119867)
1. Involvement of p53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition.
Yu X; Li H; Zhu M; Hu P; Liu X; Qing Y; Wang X; Wang H; Wang Z; Xu J; Tan R; Guo Q; Hui H
J Invest Dermatol; 2020 Oct; 140(10):2009-2022.e4. PubMed ID: 32119867
[TBL] [Abstract][Full Text] [Related]
2. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
4. Natural HDAC-1/8 inhibitor baicalein exerts therapeutic effect in CBF-AML.
Yu X; Li H; Hu P; Qing Y; Wang X; Zhu M; Wang H; Wang Z; Xu J; Guo Q; Hui H
Clin Transl Med; 2020 Aug; 10(4):e154. PubMed ID: 32898337
[TBL] [Abstract][Full Text] [Related]
5. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma.
Lopez AT; Bates S; Geskin L
Am J Clin Dermatol; 2018 Dec; 19(6):805-819. PubMed ID: 30173294
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.
Marquard L; Gjerdrum LM; Christensen IJ; Jensen PB; Sehested M; Ralfkiaer E
Histopathology; 2008 Sep; 53(3):267-77. PubMed ID: 18671804
[TBL] [Abstract][Full Text] [Related]
7. Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
Fournier JF; Bhurruth-Alcor Y; Musicki B; Aubert J; Aurelly M; Bouix-Peter C; Bouquet K; Chantalat L; Delorme M; Drean B; Duvert G; Fleury-Bregeot N; Gauthier B; Grisendi K; Harris CS; Hennequin LF; Isabet T; Joly F; Lafitte G; Millois C; Morgentin R; Pascau J; Piwnica D; Rival Y; Soulet C; Thoreau É; Tomas L
Bioorg Med Chem Lett; 2018 Sep; 28(17):2985-2992. PubMed ID: 30122227
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
9. The Epigenetic Regulator HDAC1 Modulates Transcription of a Core Cardiogenic Program in Human Cardiac Mesenchymal Stromal Cells Through a p53-Dependent Mechanism.
Moore JB; Zhao J; Keith MC; Amraotkar AR; Wysoczynski M; Hong KU; Bolli R
Stem Cells; 2016 Dec; 34(12):2916-2929. PubMed ID: 27501845
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Umamaheswari A; Puratchikody A; Hari N
Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
[TBL] [Abstract][Full Text] [Related]
11. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
12. LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK-eIF2α-ATF4-CHOP axis.
Yu XX; Zhu MY; Wang JR; Li H; Hu P; Qing YJ; Wang XY; Wang HZ; Wang ZY; Xu JY; Guo QL; Hui H
Acta Pharmacol Sin; 2021 Feb; 42(2):290-300. PubMed ID: 32747719
[TBL] [Abstract][Full Text] [Related]
13. DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors
Kwesi-Maliepaard EM; Malik M; van Welsem T; van Doorn R; Vermeer MH; Vlaming H; Jacobs H; van Leeuwen F
Front Genet; 2022; 13():1032958. PubMed ID: 36425063
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
15. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
[TBL] [Abstract][Full Text] [Related]
17. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function.
Heideman MR; Wilting RH; Yanover E; Velds A; de Jong J; Kerkhoven RM; Jacobs H; Wessels LF; Dannenberg JH
Blood; 2013 Mar; 121(11):2038-50. PubMed ID: 23327920
[TBL] [Abstract][Full Text] [Related]
18. BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.
Fu W; Yi S; Qiu L; Sun J; Tu P; Wang Y
J Invest Dermatol; 2017 Jul; 137(7):1523-1532. PubMed ID: 28288848
[TBL] [Abstract][Full Text] [Related]
19. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.
Khan O; Fotheringham S; Wood V; Stimson L; Zhang C; Pezzella F; Duvic M; Kerr DJ; La Thangue NB
Proc Natl Acad Sci U S A; 2010 Apr; 107(14):6532-7. PubMed ID: 20308564
[TBL] [Abstract][Full Text] [Related]
20. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
